Season 2023–2024 was characterized by two consecutive peaks: one in late December associated with bronchiolitis and Covid-19, the other in late January due to influenza.
Epidemic bronchiolitis usually lasted 12 weeks, but on mainland France began earlier, from mid-October. Its intensity is comparable to that observed before the emergence of Covid-19. “The impact of the nirsevimab immunization campaign and its real-life effectiveness are currently being assessed,” points out Santé Publique France, which notes that respiratory syncytial virus (RSV) “was involved in 69% of pediatric hospitalizations.” intensive therapy.
THAT COVID-19 since July 2023, its indicators have increased with two peaks in September and December, in dynamics and intensity comparable to what was observed in 2022-2023. Since mid-February, indicators have stagnated at low levels. Vaccination coverage is also low, estimated to be only 30.2% of people aged 65 and older at the end of the fall booster.
Epidemic flu lasted 10 weeks, from the end of December to the end of February. Its scale and intensity were “moderate in the city,” according to Santé Publique France. This resulted in approximately 1,540,000 consultations for influenza-like illnesses. The epidemic was caused primarily by type A(H1N1)pdm09 viruses, which are antigenically and genetically similar to the vaccine strain present in the 2023-2024 influenza vaccine. Vaccination coverage, estimated at the end of February 2024, remains insufficient and lower than in the 2022–2023 season. Only 47.1% of at-risk people who received the flu vaccine were vaccinated.
Ultimately, Public Health France concludes, the impact of acute respiratory infections on city and hospital care was “lower than in the 2022-2023 season.”
Related Posts
Cranberry extract to improve microbiota and combat cardiometabolic diseases.
The Mediterranean Diet: A Protective Diet for Everyone – Plants and Health
